Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Files China BLA for Sylvant, a Rare Disease Therapy

publication date: Jan 27, 2021

BeiGene and the UK's EUSA Pharma announced that their Sylvant^®BLA was accepted for Priority Review in China. Sylvant is a treatment for adult patients with multicentric Castleman’s disease (MCD). A rare disease, MCD is a debilitating condition of the lymph nodes and related tissues. One year ago, BeiGene acquired Greater China commercialization rights to Sylvant from EUSA as part of a $160 million two-drug in-licensing agreement. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.